Habich Carina, Kowalski Alexandra, Wachter Astrid, Heimann Michaela J, Wolf Michael, Kummer Markus P, Nicolaisen Nathalie, Sliwinski Christopher, Reinhardt Lydia, Heil Veronika, Lange Timo, Untucht Christopher, Miller Loan N, Korffmann Jürgen, Geist Daniela, Schöndorf David, Lee Heyne, Bahnassawy Lamiaa, Mielich-Süss Benjamin, Brennan Melanie S, Wilkens Ruven, Röwe Julian, Weidling Ian, Rudolf Rüdiger, Hafner Mathias, Manos Justine D, Cik Miroslav, Reinhardt Peter
AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery, Knollstrasse, 67061 Ludwigshafen, Germany.
Institute of Molecular and Cell Biology, Mannheim University of Applied Sciences, 68163 Mannheim, Germany.
Stem Cell Reports. 2025 Jul 8;20(7):102539. doi: 10.1016/j.stemcr.2025.102539. Epub 2025 Jun 19.
Human induced pluripotent stem cells (hiPSCs) are a promising tool for studying neurological diseases and developing therapies for neurodegenerative diseases. Differentiation of hiPSCs into neurons can be achieved by dual SMAD inhibition (dSMADi) or by induced neurogenin 2 (NGN2) overexpression ("iNGN2"). Starting directly from hiPSCs, iNGN2 shortens the time to a neuronal stage but leads to neurons partially resembling peripheral or posterior fates while dSMADi more faithfully recapitulates telencephalic development. To modify the iNGN2 approach, we applied an accelerated induction paradigm that is dependent on the inhibition of BMP, MEK, and WNT pathways ("BMWi"), to commit hiPSCs into a telencephalic fate before iNGN2. The resulting neurons showed strong expression of telencephalic markers, with decreased levels of peripheral and posterior marker genes compared to iNGN2 alone. The resulting telencephalic neurons are suitable for a tau aggregation assay. Furthermore, we could demonstrate that during BMWi treatment, the cells are amenable to additional regional patterning cues. This allowed the generation of neurons from different regions of the CNS and peripheral nervous system (PNS), which will significantly facilitate in vitro modeling of a range of neurodevelopmental and neurodegenerative disorders.
人诱导多能干细胞(hiPSC)是研究神经疾病和开发神经退行性疾病治疗方法的一种有前景的工具。通过双重SMAD抑制(dSMADi)或诱导神经生成素2(NGN2)过表达(“iNGN2”)可实现hiPSC向神经元的分化。直接从hiPSC开始,iNGN2缩短了达到神经元阶段的时间,但会导致神经元部分类似于外周或后脑命运,而dSMADi更忠实地模拟端脑发育。为了改进iNGN2方法,我们应用了一种依赖于抑制BMP、MEK和WNT信号通路的加速诱导模式(“BMWi”),以便在进行iNGN2之前使hiPSC定向为端脑命运。与单独使用iNGN2相比,由此产生的神经元显示出端脑标志物的强表达,外周和后脑标志物基因的水平降低。由此产生的端脑神经元适用于tau蛋白聚集分析。此外,我们能够证明在BMWi处理期间,细胞易于接受额外的区域模式化线索。这使得能够从中枢神经系统(CNS)和外周神经系统(PNS)的不同区域生成神经元,这将显著促进一系列神经发育和神经退行性疾病的体外建模。